ArticlePloS one2025
Serology change-based clinical interpretation of indeterminate serostatus post-hepatitis B virus infection in people living with HIV.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinically Relevant Risk of Hepatitis B Virus Infection and Reactivation in People With HIV After Withdrawal of Anti-HBV-Active Antiretroviral Therapy in Japan.Open forum infectious diseases · 2026Article
- High Burden of Occult Hepatitis B Infection in HIV-Infected Patients in Southern Vietnam: Insights from Serological and Molecular Analysis.International journal of molecular sciences · 2026Article
- Genetic Diversity, Occult Hepatitis B, and Mutational Signatures in Migrants from Regions with Varying HBV Endemicity: Importation of Diverse Viral Variants into St. Petersburg, Russia.International journal of molecular sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After hepatitis B virus (HBV) infection in people living with HIV (PLWH), various forms of indeterminate serostatuses, including "isolated anti-HBc (IAHBc)", are observed, but the current interpretation for their HBV immunity seems to be optimistic. This single-center, retrospective cohort study of 1,461 PLWH included individuals with past natural HBV infection and negative history of HBV vaccination. Further, based on their most recent serology status, the selected individuals were classified into either 1) seroconversion, 2) chronic infection, or 3) indeterminate groups. PLWH of the latter group (with indeterminate serostatus) were defined as neither seroconversion [HBsAg(-)/anti-HBs(+)/anti-HBc(+)] nor chronic infection [HBsAg(+)/anti-HBs(-)/anti-HBc(+)]; chronological sub-serostatus of these individuals and clinical interpretations were determined based on long-term serological changes. Of the 878 PLWH with past-HBV infection and no vaccination, seroconversion was documented in 640 (73%), chronic infection in 60 (7%), and 178 (20%) were considered the indeterminate group. Based on a review of 13-year serologic tests (9 test repeats), patients of the indeterminate group were classified as either "isolated anti-HBc (IAHBc)" (n = 118, 66%), "anti-HBs alone" (n = 35, 20%), or "lost anti-HBs/anti-HBc" (n = 25, 14.0%). None showed "resolved infection" pattern. IAHBc was significantly associated with weak HBV immunity, such as viral rebound or non-seroconversion [odds ratio (OR) 2.181, 95% confidence interval (95%CI) (1.064-4.469)], while anti-HBs alone was not [OR: 0.143, 95%CI: 0.041-0.492]. Clinical interpretations of lost anti-HBs/anti-HBc were identical to those of IAHBc. In PLWH, IAHBc and lost anti-HBs/anti-HBc do not indicate resolved but weak/unstable immunity against HBV, whereas anti-HBs alone infers robust immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.